N/A N=12 Diabetes Homelessness Medication Support Program in Spanish
Diabetes Mellitus, Type 2
Primary: Acceptability of Intervention — 30.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Improving Health Insurance Literacy Among Utah's Hispanic Population
Health Knowledge, Attitudes, Practice
Primary: Number of Enrolled Individuals — 9 participants
N/A N=260 Lung Cancer Screening Navigation for Homeless People
Lung Cancer · Tobacco Use · Homelessness
Primary: Number (Percentage) of Participants Who Receive Low-dose Computed Tomography (LDCT) for Lung Cancer Screening (LCS) at 6 Months (26 Weeks). — 8; 75 Participants — p=<0.001
N/A N=115,484 Early Detection of GEnetic Risk (EDGE)
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
Phase 2 N=126 Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention
Urological System Complication of Procedure · Urinary Tract Infections
Primary: The Main Outcome Measure Was the Incidence of Urinary Tract Infection (UTI) Post-urodynamic Study (UDS), Diagnosed Through Urinalysis Indicating Leukocyturia, Positive…
Phase 2 N=56 A Study of Guselkumab in Participants With Systemic Sclerosis
Scleroderma, Systemic
Primary: Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -9.5; 3.1 Score on a scale — p=< 0.001
Phase 3 N=12 Use of Vasopressin Following the Fontan Operation
Pleural Effusion · Single-ventricle
Primary: Chest Tube Drainage — 686.83; 535.50 ml/kg
Phase 2 N=103 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Advanced Melanoma
Primary: Objective Response Rate (ORR) — 21.4 Percentage of Participants
Phase 3 N=388 A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.7; -1.6 Percentage of glycosylated haemoglobin — p=<.0001
Phase 3 N=471 A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 — -3.77; -3.67 units on a scale
N/A N=2,016 Xeljanz Special Investigation for Long-term Use in UC Patients
Ulcerative Colitis
Primary: Number of Participants With Adverse Drug Reactions — 466; 46 Participants
Phase 1 N=28 A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Pulmonary Disease · Tuberculosis, Pulmonary · Tuberculosis
Primary: TBAJ-876 Effect on the Pharmacokinetics of the CYP-3A4 Substrate Midazolam in Healthy Adult Subjects: Pharmacokinetic Parameters AUC — 22.64; 25.22; 24.28; 25.68 ng.hr/mL
Phase 1 N=14 A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
Healthy Participants
Primary: PF-07321332 Maximum Observed Plasma Concentration (Cmax) on Day 1 — 3082 nanograms per milliliter (ng/mL)
N/A N=56 Improving Resiliency in Air Force Personnel
Military Personnel · Health Promotion
Primary: Changes in Connor-Davidson 10-Item Scale (CD-10) — 28; 28.5; 33.5; 32 score on a scale — p=.083
Phase 2 N=185 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Non-Segmental Vitiligo
Primary: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 — -14.36; -21.96; -35.63; -33.96 Percent change from baseline — p=0.304